Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Onconetix, Inc.ONCO · Entity 8471 | Director | August 15, 2025 | August 19, 2025 |
| Tribeca Strategic Acquisition Corp.BID · Entity 6357 | Director | May 28, 2026 | May 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Onconetix, Inc.
Report date August 15, 2025 · Filed August 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20 |
Reported balance
After 2025-08-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-08-15 · Other · Acquired 20 · Balance 20 F1: Represents a restricted stock award originally granted to the Reporting Person on March 23, 2025 pursuant to the Issuer's 2022 Equity Incentive Plan, as amended ("2022 Plan" and the grant on such date, the "Original Award"). On August 15, 2025, the Original Award was modified to change the vesting terms, such that the award, which was to vest in full on August 31, 2025, was changed to vest in full on August 31, 2026, so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. Except as set forth herein, the Original Award remains unmodified. F2: On June 13, 2025, the Issuer effected a 1-for-85 reverse split of its Common Stock. The amounts set forth herein are presented on a post-split basis. |
| Common StockSEC Table I · non-derivative | Direct | 638 |
Reported balance
After 2025-08-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-08-15 · Grant · Acquired 618 · Balance 638 F3: Represents a restricted stock award granted to the Reporting Person pursuant to the 2022 Plan. The award will vest in full on August 31, 2026 so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock award originally granted to the Reporting Person on March 23, 2025 pursuant to the Issuer's 2022 Equity Incentive Plan, as amended ("2022 Plan" and the grant on such date, the "Original Award"). On August 15, 2025, the Original Award was modified to change the vesting terms, such that the award, which was to vest in full on August 31, 2025, was changed to vest in full on August 31, 2026, so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. Except as set forth herein, the Original Award remains unmodified.
F2: On June 13, 2025, the Issuer effected a 1-for-85 reverse split of its Common Stock. The amounts set forth herein are presented on a post-split basis.
F3: Represents a restricted stock award granted to the Reporting Person pursuant to the 2022 Plan. The award will vest in full on August 31, 2026 so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date.
Tribeca Strategic Acquisition Corp.
Report date May 28, 2026 · Filed May 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-28 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-291431), under the heading "Description of Securities-Founder Shares," the Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the holder thereof, on a one-for-one basis, subject to certain adjustments described therein. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-291431), under the heading "Description of Securities-Founder Shares," the Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the holder thereof, on a one-for-one basis, subject to certain adjustments described therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2025 Filed Aug 19, 2025 20:05 UTC | Onconetix, Inc. ONCO · Entity 8471 | GrantCommon Stock | 618 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-078489 · ownership.xml · nonDerivative · entry 2 Oakley Andrew John · CIK 0002059152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 638 F3 · shares: Represents a restricted stock award granted to the Reporting Person pursuant to the 2022 Plan. The award will vest in full on August 31, 2026 so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:05 UTC | Onconetix, Inc. ONCO · Entity 8471 | OtherCommon Stock | 20 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-078489 · ownership.xml · nonDerivative · entry 1 Oakley Andrew John · CIK 0002059152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20 F1 · shares: Represents a restricted stock award originally granted to the Reporting Person on March 23, 2025 pursuant to the Issuer's 2022 Equity Incentive Plan, as amended ("2022 Plan" and the grant on such date, the "Original Award"). On August 15, 2025, the Original Award was modified to change the vesting terms, such that the award, which was to vest in full on August 31, 2025, was changed to vest in full on August 31, 2026, so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. Except as set forth herein, the Original Award remains unmodified. F2 · shares: On June 13, 2025, the Issuer effected a 1-for-85 reverse split of its Common Stock. The amounts set forth herein are presented on a post-split basis. F2 · balance_after: On June 13, 2025, the Issuer effected a 1-for-85 reverse split of its Common Stock. The amounts set forth herein are presented on a post-split basis. Read SEC document |
| March 23, 2025 Filed Mar 25, 2025 19:44 UTC | Onconetix, Inc. ONCO · Entity 8471 | GrantCommon Stock | 1,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001013762-25-002105 · ownership.xml · nonDerivative · entry 1 Oakley Andrew John · CIK 0002059152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,709 F1 · shares: On March 23, 2025, the Reporting Person was granted 1,709 restricted stock units, which will be settled in shares of common stock, par value $0.00001. The restricted stock units fully vest on August 31, 2025. F2 · balance_after: Includes unvested RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.